Table 1 Use of MSCs to promote engraftment in murine models

Human UCB CD34⁺cells

NOD/SCID mice

3.5 Gy

Human fetal lung

1 × 10⁶

3-4 fold increased donor CD45⁺ (lymphoid & myeloid, not B cell)

21

Human UCB CD34⁺cells

NOD/SCID mice

3.5 Gy

Fetal lung, liver, or BM or adult BM

1 × 10⁶

Fetal lung & BM & adult BM MSCs increased engraftment of donor CD45⁺ in BM, PB, or spleen

22

Human UCB CD34⁺cells (single vs double)

NOD/SCID mice

3.25 Gy

Human placenta

4 × 10⁴

Increased engraftment (total & CD34⁺), no effect on CD19⁺ Decreased single cord dominance

13

Human UCB CD34⁺cells (single vs double)

NOD/SCID mice

3.5 Gy

Human BM

NR

Increased engraftment, decreased single cord dominance

23

Human PB CD133⁺cells

NOD/SCID mice

3 Gy

Human BM; CD271⁺ & PA-MSC

1 × 10⁵(1:1; HSC:MSC) 7 × 10⁵ (1:8)

Increased engraftment (CD45⁺, CD33⁺, CD19⁺), no effect on CD41a⁺, CD3⁺, CD56⁺ Increased engraftment (CD271⁺ > PA-MSC), comparable increase CD33⁺ & CD41a⁺, CD271⁺ increase lymphoid & decrease NK cells

24

Human UCB CD34⁺cells

NOD/SCID mice

3.5 Gy

Human BM (STRO-1⁺ or STRO-1⁻)

1 × 10⁶

STRO-1⁻ MSC increased engraftment of donor CD45⁺ in BM, PB, or spleen more than STRO-1⁺, STRO-1⁺ MSC improved homing to recipient tissue

25

C57BL/6 or BALB/b TCD BM cells

BALB/c or C57BL6/-Ly-5.1 mice

5-6 Gy

Syngeneic, allogeneic, or 3rd party BM

0.25 × 10⁶; days 0, 4, 7, 10, 14

Syngenic MSCs increase engraftment, donor MSCs increase rejection, 3rd party MSCs no effect

14

Human PB CD34⁺cells

NOD/SCID mice

3 Gy

Autologous (PB) or allogeneic (BM), human

1 × 10⁶

Increased donor CD45⁺ with either MSC source, allogeneic MSCs increased myeloid engraftment and megakaryocytopoiesis

15